Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

Healthy Clinical Trial

Official title:

An Open-Label, Single-Dose, Single-Period Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05012670
• Other study ID #: KZA-0084-102
• Secondary ID: QSC204878
• Status: Completed
• Phase: Phase 1
• Start date: August 18, 2021
• Est. completion date: January 30, 2024

Study information

• Verified date: March 2024
• Source: Kazia Therapeutics Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single-centre, open-label, non-randomised study to assess the mass balance recovery, PK, metabolite profile, and metabolite identification of a single oral dose of 14C labelled paxalisib ([14C] Paxalisib) in healthy male subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: January 30, 2024
• Est. primary completion date: March 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 30 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Healthy males.

2. Aged 30 to 65 years inclusive at the time of signing informed consent.

3. Body mass index (BMI) of 18.0 to 35.0 kg/m2 as measured at screening.

4. Must be willing and able to communicate and participate in the whole study.

5. Must have regular bowel movements (i.e., average stool production of =1 and =3 stools per day).

6. Must provide written informed consent.

7. Must agree to adhere to the contraception requirements defined in study protocol.

Exclusion Criteria:

1. Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1.

2. Subjects who are, or are immediate family members of, a study site or sponsor employee.

3. Evidence of current SARS-CoV-2 infection.

4. History of any drug or alcohol abuse in the past 2 years.

5. Regular alcohol consumption >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).

6. A confirmed positive alcohol breath test at screening or admission.

7. Current smokers and those who have smoked within the last 12 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission.

8. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months.

9. Subjects with pregnant or lactating partners.

10. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study.

11. Subjects who have been administered IMP in an ADME study in the last 12 months.

12. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening.

13. Clinically significant abnormal clinical chemistry, haematology, or urinalysis as judged by the investigator (laboratory parameters are listed in study protocol).

14. Confirmed positive drugs of abuse test result (drugs of abuse tests are listed in study protocol)

15. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus (HIV) antibody results

16. Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance (CLcr) of <80 mL/min using the Cockcroft-Gault equation.

17. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory disease, neurological, or psychiatric disorder, as judged by the investigator.

18. History of clinically significant GI disease, especially peptic ulceration, GI bleeding, ulcerative colitis, Crohn's Disease, or Irritable Bowel Syndrome.

19. Any history of pre-diabetes, diabetes mellitus (any type), or hyperglycaemia. At screening, fasting blood glucose and HbA1c must be within the normal range.

20. History or presence of significant dermatological disorders or skin rashes, as judged by the investigator.

21. Subject had a QTcF of >450 msec based on ECG at screening or at pre dose, or a history of additional risk factors for Torsades de Pointe (e.g., hypokalaemia, hypomagnesia, a family history of long QT syndrome).

22. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients.

23. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active.

24. Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood.

25. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day) within 14 days before IMP administration (see Section 11.4). COVID-19 vaccines are accepted concomitant medications, except for within 72 h of dosing. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the investigator.

26. Subjects who have had a COVID-19 vaccine within 72 h (3 days) before IMP administration.

27. History of GI surgery (with the exception of appendectomy unless it was performed within the previous 12 months).

28. Acute diarrhoea or constipation in the 7 days before the predicted Day 1. If screening occurs >7 days before the Day 1, this criterion will be determined on Day 1. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than 3 times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day.

29. Failure to satisfy the investigator of fitness to participate for any other reason.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• [14C]-Paxalisib Capsule
Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.

Locations

Country	Name	City	State
United Kingdom	Quotient Sciences	Nottingham

Sponsors (2)

Lead Sponsor	Collaborator
Kazia Therapeutics Limited	Quotient Sciences

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To assess the urine PK of paxalisib following administration of [14C] Paxalisib	Determination of [14C] Paxalisib and calculation of Ae (amount excreted), CumAe (cummulative amount excreted), %Ae (fraction of dose excreted) and Cum%Ae (cummulative fraction of dose excreted) as appropriate for paxalisib in urine	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Primary	To determine the mass balance recovery after a single oral dose of carbon-14 ([14C])-Paxalisib	Mass balance recovery of total radioactivity (TR) in all excreta (urine and faeces): CumAe (amount excreted) and Cum%Ae	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Primary	To provide plasma samples for metabolite profiling and structural identification	Collection of plasma samples for metabolite profiling, structural identification, and quantification analysis of paxalisib metabolites	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Primary	To provide urine samples for metabolite profiling and structural identification	Collection of urine samples for metabolite profiling, structural identification, and quantification analysis of paxalisib metabolites	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Primary	To provide faecal samples for metabolite profiling and structural identification	Collection of faecal samples for metabolite profiling, structural identification, and quantification analysis of paxalisib metabolites	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To determine the routes and rates of elimination of [14C]-Paxalisib	Calculation of Ae, %Ae, CumAe, and Cum%Ae for TR by interval in urine and faeces	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To identify the chemical structure of each metabolite accounting for more than 10% (in plasma) of circulating TR or metabolites in excreta (urine and faeces) that account for more than 10% of the administered radioactive dose	Identification of the chemical structure of each paxalisib metabolite accounting for more than 10% by area under the curve (AUC) of circulating TR in plasma to identify major metabolites, and identification of each metabolite in excreta (urine and faeces) that accounts for more than 10% of the administered radioactive dose	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To explore the Cmax pharmacokinetic (PK) parameter of paxalisib following administration of [14C] Paxalisib	Assessment of the PK of an oral [14C]-Paxalisib formulation by measurement of paxalisib in plasma including but not limited to Cmax parameter	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To explore the Tmax pharmacokinetic (PK) parameter of paxalisib following administration of [14C] Paxalisib	Assessment of the PK of an oral [14C]-Paxalisib formulation by measurement of paxalisib in plasma including but not limited to Tmax parameter	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To explore the AUC(0-last) and AUC(0-inf) pharmacokinetic (PK) parameter of paxalisib following administration of [14C] Paxalisib	Assessment of the PK of an oral [14C]-Paxalisib formulation by measurement of paxalisib in plasma including but not limited to AUC(0-last) and AUC(0-inf) parameter	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To explore the Cmax pharmacokinetic (PK) of TR following administration of [14C] Paxalisib	Assessment of the PK of an oral [14C]-Paxalisib formulation by measurement of TR in plasma including but not limited to Cmax parameter	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To explore the Tmax pharmacokinetic (PK) of TR following administration of [14C] Paxalisib	Assessment of the PK of an oral [14C]-Paxalisib formulation by measurement of TR in plasma including but not limited to Tmax parameter	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To explore the AUC(0-last) and AUC(0-inf) pharmacokinetic (PK) of TR following administration of [14C] Paxalisib	Assessment of the PK of an oral [14C]-Paxalisib formulation by measurement of TR in plasma including but not limited to AUC(0-last) and AUC(0-inf) parameter	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To evaluate the extent of distribution of TR into blood cells	Evaluation of whole blood:plasma concentration ratios for TR	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To provide adverse event (AE) safety information for paxalisib	To provide safety information for paxalisib by assessing adverse events.	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To provide blood pressure vital sign safety information for paxalisib	Measuring and assessing blood pressure in standard clinical units and against reference range.	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To provide heart rate vital sign safety information for paxalisib	Measuring and assessing heart rate in standard clinical units against reference range.	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To provide oral temperature vital sign safety information for paxalisib	Measuring and assessing oral temperature in standard clinical units against reference range.	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To provide respiratory rate vital sign safety information for paxalisib	Measuring and assessing respiratory rate in standard clinical units against reference range .	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To provide electrocardiogram (ECG) safety information for paxalisib	Determination of standard ECG parameters including but not limited to PR interval, QRS duration, in standard clinical units against reference range	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To provide physical examination safety information for paxalisib	Assessment of standard clinical whole-body targeted (symptom-driven) physical examination including but not limited to e.g. general appearance, dermatological	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To provide hematology laboratory safety testing information for paxalisib	Measuring and assessing standard array of hematology parameters (e.g. white blood cell count) in standard clinical unit against reference range.	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Secondary	To provide clinical chemistry laboratory safety testing information for paxalisib	Measuring and assessing standard array of clinical chemistry parameters (e.g. cholesterol) in standard clinical unit against reference range	Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)